The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
REGULATORY
Breyanzi to Join NHI List on May 19 at Post-CEA-Adjusted Kymriah Price
Celgene’s third-in-class CAR-T cell therapy Breyanzi (lisocabtagene maraleucel; liso-cel) will be added to the NHI price list in Japan on May 19 at the same price as Kymriah’s (tisagenlecleucel) post cost-effectiveness assessment (CEA)-based adjustment price. Breyanzi’s listing was supported by…
To read the full story
Related Article
- Drug Pricing Rules to Be Applied to Breyanzi: Chuikyo
April 15, 2021
- Yescarta to Join NHI Price List on April 21, Gets CEA-Tweak from Get-Go
April 14, 2021
- Kymriah to Face 4% Price Cut in 1st CEA-Based Price Tweak, Yescarta Too
April 13, 2021
- Japan Approves 3rd CAR-T Cell Therapy, Celgene’s Breyanzi
March 23, 2021
REGULATORY
- Japan Govt OKs Economic Package to Counter US Tariff Impact
April 28, 2025
- ASKA’s Contraceptive, Vabysmo Label Expansion Now in Line for Japan Approval
April 28, 2025
- MHLW/PMDA, FDA Philippines to Boost Regulatory Cooperation
April 28, 2025
- LDP Members Raise No Call for Tax Cuts, Fret Inflationary Impact on Medical Facilities: Fiscal Reform HQ
April 25, 2025
- Japan to Buttress Regulatory Communication Efforts for Drug Originators Overseas
April 25, 2025
Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…